The Standard Process price increase and MediHerb price increase have practitioners talking, and they have a right to feel frustrated. This affects inventory, recommendations, protocols, and what patients can realistically afford. But the real problem is not just the price increase. It is what happens when frustration starts driving decisions that should still be clinical.
After a Facebook post in December lit up the practitioner community, I saw reactions all over the board. Some people were frustrated. Some were ready to make big changes. Others were more neutral. And honestly, I understand all of it.
But being frustrated with a company and making the best decision for a patient are not the same thing.
In this episode, I'm sharing my perspective on the whole conversation, including my own history with Standard Process, what the pricing data actually showed when I went back and looked at it, and the five questions I think practitioners need to ask before they start changing products, switching companies, or reworking protocols out of irritation.
In this episode, I cover:
What the price data from 2022 to 2026 actually showed
Why MediHerb and Standard Process are not exactly the same conversation
Why being mad is not a treatment strategy
The five questions to ask before changing products, brands, or protocols
When a higher-priced product may still be the better clinical and financial choice
This is an honest conversation about pricing, clinical judgment, and keeping the patient at the center of the decision.
And if you want support making clinical decisions like this with more confidence, come join us in Clinical Academy.
